Carrie  Eglinton Manner net worth and biography

Carrie Eglinton Manner Biography and Net Worth

Director of Repligen
Carrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 25 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as President and CEO of OraSure Technologies, Inc. (“OraSure”), which she joined in June 2022. OraSure is a leader in the development, manufacture and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular service solutions designed to discover and detect critical medical conditions. Prior to OraSure, Ms. Eglinton Manner served as Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics (“Quest”), which she joined in 2017. In her role at Quest, Ms. Eglinton Manner was responsible for value creation across the company’s $10 billion clinical portfolio, driving innovation in R&D, along with partnerships and acquisitions. She helped accelerate growth in Quest’s $2 billion Advanced Diagnostics portfolio, which included its specialty molecular and genetic offerings, along with Quest’s global and pharmaceutical services businesses. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In addition to the Repligen Board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and building healthy, resilient communities. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.

What is Carrie Eglinton Manner's net worth?

The estimated net worth of Carrie Eglinton Manner is at least $350,817.48 as of March 16th, 2022. Ms. Eglinton Manner owns 2,106 shares of Repligen stock worth more than $350,817 as of April 27th. This net worth approximation does not reflect any other investments that Ms. Eglinton Manner may own. Learn More about Carrie Eglinton Manner's net worth.

How do I contact Carrie Eglinton Manner?

The corporate mailing address for Ms. Eglinton Manner and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Carrie Eglinton Manner's contact information.

Has Carrie Eglinton Manner been buying or selling shares of Repligen?

Carrie Eglinton Manner has not been actively trading shares of Repligen in the last ninety days. Most recently, on Wednesday, March 16th, Manner Carrie Eglinton bought 625 shares of Repligen stock. The stock was acquired at an average cost of $175.02 per share, with a total value of $109,387.50. Following the completion of the transaction, the director now directly owns 2,106 shares of the company's stock, valued at $368,592.12. Learn More on Carrie Eglinton Manner's trading history.

Who are Repligen's active insiders?

Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (CEO), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.

Are insiders buying or selling shares of Repligen?

In the last year, Repligen insiders bought shares 2 times. They purchased a total of 1,000 shares worth more than $158,665.00. In the last year, insiders at the biotechnology company sold shares 6 times. They sold a total of 30,235 shares worth more than $5,742,533.77. The most recent insider tranaction occured on March, 11th when VP Ralf Kuriyel sold 3,517 shares worth more than $681,348.41. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.

Information on this page was last updated on 3/11/2024.

Carrie Eglinton Manner Insider Trading History at Repligen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2022Buy625$175.02$109,387.502,106View SEC Filing Icon  
See Full Table

Carrie Eglinton Manner Buying and Selling Activity at Repligen

This chart shows Manner Carrie Eglinton's buying and selling at Repligen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Repligen Company Overview

Repligen logo
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $166.58
Low: $165.05
High: $168.46

50 Day Range

MA: $184.21
Low: $157.06
High: $208.42

2 Week Range

Now: $166.58
Low: $110.45
High: $211.13

Volume

341,269 shs

Average Volume

463,708 shs

Market Capitalization

$9.30 billion

P/E Ratio

231.36

Dividend Yield

N/A

Beta

1.02